ZEAL.CO vs. GMAB

Last updated Apr 3, 2026

Compare and contrast key facts about Zealand Pharma A/S (ZEAL.CO) and Genmab A/S (GMAB).

Performance

ZEAL.CO vs. GMAB - Performance Comparison

The chart below illustrates the hypothetical performance of a DKK 10,000 investment in Zealand Pharma A/S (ZEAL.CO) and Genmab A/S (GMAB). The values are adjusted to include any dividend payments, if applicable.

ZEAL.CO vs. GMAB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ZEAL.CO Zealand Pharma A/S	-36.11%	-34.81%	91.72%	85.30%	38.80%	-34.22%	-6.29%	185.68%	-3.06%	-20.19%
GMAB Genmab A/S	-10.08%	30.29%	-30.10%	-26.94%	13.81%	4.43%	66.42%	38.71%	4.31%	-12.24%

Different Trading Currencies

ZEAL.CO is traded in DKK, while GMAB is traded in USD. To make them comparable, the GMAB values have been converted to DKK using the latest available exchange rates.

Returns By Period

In the year-to-date period, ZEAL.CO achieves a -36.11% return, which is significantly lower than GMAB's -10.08% return. Over the past 10 years, ZEAL.CO has outperformed GMAB with an annualized return of 8.57%, while GMAB has yielded a comparatively lower 6.66% annualized return.

ZEAL.CO

• 1D: 1.02%
• 1M: -16.41%
• YTD: -36.11%
• 6M: -40.97%
• 1Y: -35.97%
• 3Y*: 11.53%
• 5Y*: 8.24%
• 10Y*: 8.57%

GMAB

• 1D: 0.00%
• 1M: -1.04%
• YTD: -10.08%
• 6M: -13.95%
• 1Y: 36.18%
• 3Y*: -11.80%
• 5Y*: -3.27%
• 10Y*: 6.66%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ZEAL.CO vs. GMAB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ZEAL.CO

ZEAL.CO Risk / Return Rank: 15
ZEAL.CO Sharpe Ratio Rank: 16
ZEAL.CO Sortino Ratio Rank: 20
ZEAL.CO Omega Ratio Rank: 20
ZEAL.CO Calmar Ratio Rank: 12
ZEAL.CO Martin Ratio Rank: 5

GMAB

GMAB Risk / Return Rank: 74
GMAB Sharpe Ratio Rank: 80
GMAB Sortino Ratio Rank: 73
GMAB Omega Ratio Rank: 71
GMAB Calmar Ratio Rank: 71
GMAB Martin Ratio Rank: 73

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ZEAL.CO vs. GMAB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Zealand Pharma A/S (ZEAL.CO) and Genmab A/S (GMAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ZEAL.CO	GMAB	Difference
Sharpe ratio Return per unit of total volatility	-0.55	1.06	-1.62
Sortino ratio Return per unit of downside risk	-0.40	1.55	-1.96
Omega ratio Gain probability vs. loss probability	0.94	1.20	-0.26
Calmar ratio Return relative to maximum drawdown	-0.77	1.28	-2.05
Martin ratio Return relative to average drawdown	-1.65	3.57	-5.21
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ZEAL.CO vs. GMAB - Sharpe Ratio Comparison

The current ZEAL.CO Sharpe Ratio is -0.55, which is lower than the GMAB Sharpe Ratio of 1.06. The chart below compares the historical Sharpe Ratios of ZEAL.CO and GMAB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ZEAL.CO	GMAB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.55	1.06	-1.62
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.14	-0.10	+0.24
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.17	0.19	-0.03
Sharpe Ratio (All Time) Calculated using the full available price history	0.18	0.31	-0.13

Correlation

The correlation between ZEAL.CO and GMAB is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ZEAL.CO vs. GMAB - Dividend Comparison

Neither ZEAL.CO nor GMAB has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ZEAL.CO vs. GMAB - Drawdown Comparison

The maximum ZEAL.CO drawdown since its inception was -75.53%, smaller than the maximum GMAB drawdown of -84.57%. Use the drawdown chart below to compare losses from any high point for ZEAL.CO and GMAB.

Drawdown Indicators

	ZEAL.CO	GMAB	Difference
Max Drawdown Largest peak-to-trough decline	-75.53%	-84.20%	+8.67%
Max Drawdown (1Y) Largest decline over 1 year	-56.96%	-28.98%	-27.98%
Max Drawdown (5Y) Largest decline over 5 years	-75.38%	-63.10%	-12.28%
Max Drawdown (10Y) Largest decline over 10 years	-75.53%	-63.10%	-12.43%
Current Drawdown Current decline from peak	-68.76%	-43.56%	-25.20%
Average Drawdown Average peak-to-trough decline	-29.52%	-30.93%	+1.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	26.76%	10.34%	+16.42%

Volatility

ZEAL.CO vs. GMAB - Volatility Comparison

Zealand Pharma A/S (ZEAL.CO) has a higher volatility of 48.77% compared to Genmab A/S (GMAB) at 7.64%. This indicates that ZEAL.CO's price experiences larger fluctuations and is considered to be riskier than GMAB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ZEAL.CO	GMAB	Difference
Volatility (1M) Calculated over the trailing 1-month period	48.77%	7.64%	+41.13%
Volatility (6M) Calculated over the trailing 6-month period	58.53%	23.51%	+35.02%
Volatility (1Y) Calculated over the trailing 1-year period	66.35%	34.17%	+32.18%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	59.85%	32.12%	+27.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	52.09%	34.55%	+17.54%

Financials